Published By : 06 Jun 2018 | Published By : QYRESEARCH
A company operating in the field of medical robotics has recently received clearance from the FDA for marketing a technology that can help healthcare providers in assessing patients that require treatment in a cost effective manner. The technology has been developed by Neural Analytics through the combination of digital information systems and the ultrasound technology. The technology is expected to help emergency healthcare providers as they examine patients for medical conditions such as stroke, which is a health issue that affects nearly 795,000 people every year in the U.S. alone.
The company has received the approval for its robotic assistance technology that can adjust position and orientation of its ultrasound products automatically, under the guidance of a qualified healthcare provider. This system, named NeuralBot System, when used with its previously cleared next generation brain damage assessment technology-Lucid M1 Transcranial Doppler Ultrasound- can assist in the nom-invasive assessment of blood flow and diagnosis of specific conditions in patients.
As the fast diagnosis of the specific medical condition in patients can help providers in beginning the proper course of treatment quickly, especially when it comes to conditions such as stroke which are time-sensitive and need intervention at the earliest for good results, this intervention can prove to be a life saver. The lack of low cost and effective patient diagnostic data negatively affects the treatment of neurological conditions. This results in delay in treatment, misdiagnosis, and additional expenses for patients. This new technology, on the other hand, can assist healthcare personnel and enable them to reach to a proper diagnostic understanding in cases when expert technicians are not available.